1. Home
  2. NBY vs XFOR Comparison

NBY vs XFOR Comparison

Compare NBY & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovaBay Pharmaceuticals Inc.

NBY

NovaBay Pharmaceuticals Inc.

HOLD

Current Price

$0.77

Market Cap

398.2M

Sector

N/A

ML Signal

HOLD

Logo X4 Pharmaceuticals Inc.

XFOR

X4 Pharmaceuticals Inc.

HOLD

Current Price

$3.56

Market Cap

323.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBY
XFOR
Founded
2000
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
398.2M
323.5M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
NBY
XFOR
Price
$0.77
$3.56
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$28.50
AVG Volume (30 Days)
2.4M
420.2K
Earning Date
11-07-2025
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.47
N/A
Revenue
$10,302,000.00
$33,979,000.00
Revenue This Year
$23.91
$1,266.01
Revenue Next Year
$32.05
N/A
P/E Ratio
$30.13
N/A
Revenue Growth
390.34
2925.74
52 Week Low
$0.46
$1.35
52 Week High
$19.95
$17.96

Technical Indicators

Market Signals
Indicator
NBY
XFOR
Relative Strength Index (RSI) 35.42 41.78
Support Level $0.75 $3.52
Resistance Level $2.13 $3.74
Average True Range (ATR) 0.58 0.18
MACD -0.61 -0.02
Stochastic Oscillator 0.26 7.56

Price Performance

Historical Comparison
NBY
XFOR

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Share on Social Networks: